ALSO NOTED: Cell Therapeutics to bypass interim analysis; Nabi reports NicVAX data; Chinese see value in scientific failure; an

> Cell Therapeutics has decided to bypass an interim analysis of  its non-Hodglin's lymphoma drug candidate Pixantrone. Instead, researchers say they will conduct a full analysis after the trial is completed later this year. Report

> Nabi reports positive results from nine-month results for NicVAX. Report

> Chinese officials are mulling a new law that will officially sanction the value of scientific failure. FierceBioResearcher

> Innocoll is selling its CollaRx Gentamicin surgical implant and European sales and marketing infrastructure to EUSA Pharma. Release

> Pfizer announced results from a new trial that showed statin-switching isn't such a good idea. Lipitor patients who switched to simvastatin saw their risk of cardio events and death rise by almost a third. FiercePharma

> AstraZeneca announced it has issued $6.9 billion in bonds on the U.S. market, planning to use the proceeds to retire a chunk of the short-term debt it took on for the $15 billion MedImmune buyout. Report

And Finally... It's tough enough worrying that the fellow in the next desk will beat you to that promotion--and now, Pfizerites have to worry about a colleague stealing their identities, too. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.